UroGen Pharma Ltd (URGN) stock news · rev $109.8M
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
This URGN news page leads with what UroGen Pharma Ltd filed — not a scraped headline mill.
No cached 8-K sentence for URGN yet. We will not pad this page with generic market recap.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. Revenue was up 538.6% from 2023-03-31 to 2025-12-31. URGN currently screens at market cap $1.61B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the URGN stock page; for the tape open the quote page.
URGN stock news FAQ
What are URGN's latest revenue and net income?
Latest cached UroGen Pharma Ltd (URGN) revenue for Dec 31, 2025 was $109.8M. Net income was -$153.5M. Statements: https://lician.com/financials/urgn
How did URGN revenue change from the prior cached period?
Cached UroGen Pharma Ltd (URGN) revenue was up 538.6% from $17.2M (Mar 31, 2023) to $109.8M (Dec 31, 2025). Statements: https://lician.com/financials/urgn
What is URGN's market cap?
UroGen Pharma Ltd (URGN) market cap is $1.61B on the latest cached fundamentals snapshot.
What kind of company is URGN?
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Where is URGN stock news listed?
Cached stock news for UroGen Pharma Ltd (URGN) is listed at https://lician.com/news/urgn. Filings: https://lician.com/sec/urgn
Not investment advice.